Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication
出版年份 2013 全文链接
标题
Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication
作者
关键词
-
出版物
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume 28, Issue 6, Pages 771-780
出版商
Wiley
发表日期
2013-05-08
DOI
10.1111/jdv.12175
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up
- (2012) Giuseppe Cianchini et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients
- (2012) Yael A. Leshem et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Immunoadsorption in Dermatology
- (2012) Damian Meyersburg et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Recommandations des centres de référence des maladies bulleuses auto-immunes pour le diagnostic et la prise en charge du pemphigus
- (2011) P. Joly et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- Rituximab for Patients With Refractory Mucous Membrane Pemphigoid
- (2011) Christelle Le Roux-Villet ARCHIVES OF DERMATOLOGY
- Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients
- (2011) J.H. Kim et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients
- (2011) M. Kasperkiewicz et al. BRITISH JOURNAL OF DERMATOLOGY
- Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris
- (2011) M. Behzad et al. BRITISH JOURNAL OF DERMATOLOGY
- Low-dose rituximab is effective in pemphigus
- (2011) B. Horváth et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment of subepidermal immunobullous diseases
- (2011) Donna A. Culton et al. CLINICS IN DERMATOLOGY
- Therapieresistentes Anti-Laminin-332-Schleimhautpemphigoid
- (2011) A. Recke et al. HAUTARZT
- Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
- (2011) Dedee F. Murrell et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Intravenous Immunoglobulin Therapy in Autoimmune Mucocutaneous Blistering Diseases
- (2010) Hakan M. Gürcan et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Immunoadsorption in dermatology
- (2010) Enno Schmidt et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients
- (2010) S. Lourari et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab
- (2008) Martin Pfütze et al. DERMATOLOGY
- Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases
- (2008) Michael Hertl et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Rituximab Immunotherapy in Pemphigus: Therapeutic Effects Beyond B-Cell Depletion
- (2008) Giovanna Zambruno et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Rituximab Exerts a Dual Effect in Pemphigus Vulgaris
- (2008) Rüdiger Eming et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
- (2008) Dedee F. Murrell et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started